Commission Implementing Decision (EU) 2026/1420 of 30 June 2026 on the non-approval of terbutryn, 1,2-Benzisothiazol-3(2H)-one (BIT) and tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) as existing active substances for use in biocidal products of product-types 9, 9, and 12, respectively, in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Date: 2026-06-30
Institutions: Directorate-General for Health and Food Safety, European Commission
Subjects: biocide, chemical product, market approval, preservative








L_202601420EN.000101.fmx.xml












Official Journal of the European Union


EN
L series













2026/1420


3.7.2026







            COMMISSION IMPLEMENTING DECISION (EU) 2026/1420
of 30 June 2026
         
on the non-approval of terbutryn, 1,2-Benzisothiazol-3(2H)-one (BIT) and tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) as existing active substances for use in biocidal products of product-types 9, 9, and 12, respectively, in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
(Text with EEA relevance)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (1), and in particular Article 89(1), third subparagraph, thereof,

Whereas:







(1)


Commission Delegated Regulation (EU) No 1062/2014 (2) establishes in its Annex II a list of active substance/product-type combinations included in the review programme of existing active substances in biocidal products.












(2)


For a number of active substance/product-type combinations included in that list, all the participants have withdrawn or are considered to have withdrawn their support in a timely manner.












(3)


In accordance with Article 14(1) of Delegated Regulation (EU) No 1062/2014, the European Chemicals Agency (‘the Agency’) published an open invitation to take over the role of participant for those active substance/product-type combinations for which the role of a participant had not previously been taken over. For those combinations no notification has been submitted to the Agency within the time limit provided for by Article 14(2) of Delegated Regulation (EU) No 1062/2014. Therefore, those active substance/product-type combinations, in accordance with Article 20, first paragraph, point (b), of that Delegated Regulation, should not be approved for use in biocidal products. Those active substance/product-type combinations are the following:






(a)


terbutryn (product-type 9);










(b)


1,2-Benzisothiazol-3(2H)-one (BIT) (product-type 9);










(c)


tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) (product-type 12).
















(4)


The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Biocidal Products,





HAS ADOPTED THIS DECISION:



Article 1
The active substances listed in the Annex are not approved as existing active substances for use in biocidal products of the product-types indicated therein.


Article 2
This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.




Done at Brussels, 30 June 2026.


For the Commission


The President

Ursula VON DER LEYEN
            





(1)  
            OJ L 167, 27.6.2012, p. 1, ELI: http://data.europa.eu/eli/reg/2012/528/oj.

(2)  Commission Delegated Regulation (EU) No 1062/2014 of 4 August 2014 on the work programme for the systematic examination of all existing active substances contained in biocidal products referred to in Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 294, 10.10.2014, p. 1, ELI: http://data.europa.eu/eli/reg_del/2014/1062/oj).




ANNEX
Active substance/product-type combinations not approved:











Entry Number in Annex II to Regulation (EU) No 1062/2014




Substance name




Rapporteur Member State




EC number




CAS number




Product-type(s)





283 


Terbutryn


SK


212-950-5


886-50-0


9 




339 


1,2-Benzisothiazol-3(2H)-one (BIT)


ES


220-120-9


2634-33-5


9 




382 


Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD)


ES


226-408-0


5395-50-6


12 







ELI: http://data.europa.eu/eli/dec_impl/2026/1420/oj
ISSN 1977-0677 (electronic edition)